-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HZuFJ8UoIflrp86CKa9xWJXnVYomqd3qg9w/9HUOSyDH8phEQBN3AnvQOQo900gC cQQS64zF36H+XjZwxHT/Kg== 0000950144-01-002505.txt : 20010223 0000950144-01-002505.hdr.sgml : 20010223 ACCESSION NUMBER: 0000950144-01-002505 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20010214 GROUP MEMBERS: PHARMABIO DEVELOPMENT INC GROUP MEMBERS: QUINTILES TRANSNATIONAL CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINES CO/ MA CENTRAL INDEX KEY: 0001113481 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043324394 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-60201 FILM NUMBER: 1539552 BUSINESS ADDRESS: STREET 1: ONE CAMBRIDGE CTR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6172259099 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: QUINTILES TRANSNATIONAL CORP CENTRAL INDEX KEY: 0000919623 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561714315 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 4709 CREEKSTONE DR STREET 2: RIVERBIRCH BLDG STE 200 CITY: DURHAM STATE: NC ZIP: 27703-8411 BUSINESS PHONE: 9199982000 MAIL ADDRESS: STREET 1: 4709 CREEKSTONE DR STREET 2: STE 300 CITY: DURHAM STATE: NC ZIP: 27703-8411 SC 13G 1 g66926bsc13g.txt THE MEDICINES COMPANY/QUINTILES TRANSNATIONAL 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 THE MEDICINES COMPANY (Name of Issuer) (Amendment No. )* COMMON STOCK, $.001 PAR VALUE PER SHARE --------------------------------------- (Title of Class of Securities) 584688-10-5 -------------- (CUSIP Number) JULY 28, 2000 ------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [X] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) Page 1 of 8 Pages. 2
- ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 2 of 8 Pages - ------------------------- --------------------- - ------------------------------------------------------------------------------------ 1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only) Quintiles Transnational Corp. 56-1714315 - ------------------------------------------------------------------------------------ 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] Joint Filing - ------------------------------------------------------------------------------------ 3) SEC USE ONLY - ------------------------------------------------------------------------------------ 4) CITIZENSHIP OR PLACE OF ORGANIZATION North Carolina - ------------------------------------------------------------------------------------ 5) SOLE VOTING POWER NUMBER OF -0- SHARES --------------------------------------------------------- BENEFICIALLY 6) SHARED VOTING POWER OWNED BY EACH 1,978,630(1) REPORTING --------------------------------------------------------- PERSON 7) SOLE DISPOSITIVE POWER WITH -0- --------------------------------------------------------- 8) SHARED DISPOSITIVE POWER 1,978,630(1) - ------------------------------------------------------------------------------------ 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,978,630(1) - ------------------------------------------------------------------------------------ 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - ------------------------------------------------------------------------------------ 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.47%(2) - ------------------------------------------------------------------------------------ 12) TYPE OF REPORTING PERSON (See Instructions) CO - ------------------------------------------------------------------------------------
(1) Includes (i) 1,696,245 shares of common stock of The Medicines Company (the "Issuer"), par value $0.001 per share ("Common Stock"), held by PharmaBio Development Inc. ("PharmaBio"), a wholly-owned subsidiary of Quintiles Transnational Corp. ("Quintiles"), which are reported by PharmaBio on the following page, and (ii) warrants, held by Quintiles, to purchase 282,385 shares of Common Stock, which are exercisable within 60 days. (2) Calculated based on 30,320,450 shares of outstanding Common Stock of the Issuer on December 31, 2000, as reported in the Issuer's Form S-1/A filing with the Securities and Exchange Commission on January 26, 2001 and on an as-converted basis with respect to the 282,385 shares represented by the warrants held by Quintiles. 3
- ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 3 of 8 Pages - ------------------------- --------------------- - ------------------------------------------------------------------------------------ 1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only) PharmaBio Development Inc. 56-2019326 - ------------------------------------------------------------------------------------ 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] Joint Filing - ------------------------------------------------------------------------------------ 3) SEC USE ONLY - ------------------------------------------------------------------------------------ 4) CITIZENSHIP OR PLACE OF ORGANIZATION North Carolina - ------------------------------------------------------------------------------------ 5) SOLE VOTING POWER NUMBER OF -0- SHARES ------------------------------------------------------------ BENEFICIALLY 6) SHARED VOTING POWER OWNED BY EACH 1,978,630(3) REPORTING ------------------------------------------------------------ PERSON 7) SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------ 8) SHARED DISPOSITIVE POWER 1,978,630(3) - ------------------------------------------------------------------------------------ 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,978,630(3) - ------------------------------------------------------------------------------------ 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - ------------------------------------------------------------------------------------ 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.47%(4) - ------------------------------------------------------------------------------------ 12) TYPE OF REPORTING PERSON (See Instructions) CO - ------------------------------------------------------------------------------------
(3) Includes (i) 1,696,245 shares of common stock of The Medicines Company (the "Issuer"), par value $0.001 per share ("Common Stock"), held by PharmaBio Development Inc. ("PharmaBio"), a wholly-owned subsidiary of Quintiles Transnational Corp. ("Quintiles") and (ii) warrants, held by Quintiles, to purchase 282,385 shares of Common Stock, which are exercisable within 60 days. (4) Calculated based on 30,320,450 shares of outstanding Common Stock of the Issuer on December 31, 2000, as reported in the Issuer's Form S-1/A filing with the Securities and Exchange Commission on January 26, 2001 and on an as-converted basis with respect to the 282,385 shares represented by the warrants held by Quintiles. 4 - ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 4 of 8 Pages - ------------------------- --------------------- ITEM 1. (A) Name of Issuer The Medicines Company (the "Issuer") (B) Address of Issuer's Principal Executive Offices One Cambridge Center, Cambridge, Massachusetts 02142 ITEM 2. (A) Name of Person Filing This statement is filed jointly on behalf of Quintiles Transnational Corp. ("Quintiles") and PharmaBio Development Inc. ("PharmaBio"), a wholly-owned subsidiary of Quintiles, pursuant to Rule 13d-1(k)(1). (B) Address of Principal Business Office or, if none, Residence Quintiles' principal business office is at 4709 Creekstone Drive, Suite 200, Durham, North Carolina 27703. PharmaBio's principal business office is c/o Quintiles Transnational Corp., 4709 Creekstone Drive, Suite 200, Durham, North Carolina 27703. (C) Citizenship: Quintiles is a North Carolina corporation. PharmaBio is also a North Carolina corporation. (D) Title of Class of Securities Common stock, par value $0.001 per share ("Common Stock") (E) CUSIP Number 584688-10-5 ITEM 3 Not applicable. ITEM 4. Ownership (a) Amount Beneficially Owned: 1,978,630 shares. (b) Percent of Class: Such 1,978,630 shares are 6.47% of the Issuer's Common Stock based on the 30,320,450 shares reported as outstanding as of December 31, 2000, in the Issuer's Form S-1/A filing with the Securities and Exchange Commission on January 26, 2001, and based on a deemed conversion with respect to the 282,385 shares represented by the warrants held by Quintiles. (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: -0- (ii) shared power to vote or to direct the vote: 1,978,630 (iii) sole power to dispose or to direct the disposition of: -0- (iv) shared power to dispose or to direct the disposition of: 1,978,630 5 - ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 5 of 8 Pages - ------------------------- --------------------- ITEM 5 Ownership of Five Percent or Less of a Class Not Applicable ITEM 6 Ownership of More than Five Percent on Behalf of Another Person Not Applicable ITEM 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable ITEM 8 Identification and Classification of Members of the Group Not Applicable ITEM 9 Notice of Dissolution of Group Not Applicable ITEM 10 Certification Not Applicable Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 14, 2001 QUINTILES TRANSNATIONAL CORP. By: /s/ James L. Bierman -------------------------------- Name: James L. Bierman Title: Chief Financial Officer PHARMABIO DEVELOPMENT INC. By: /s/ James L. Bierman -------------------------------- Name: James L. Bierman Title: Vice President and Treasurer 6 - ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 6 of 8 Pages - ------------------------- --------------------- EXHIBIT INDEX Exhibit Number Description 1 Joint Filing Agreement between Quintiles Transnational Corp. and PharmaBio Development Inc. EX-99.1 2 g66926bex99-1.txt JOINT FILING AGREEMENT 1 - ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 7 of 8 Pages - ------------------------- --------------------- Exhibit 1 Joint Filing Agreement (Attached) 2 - ------------------------- --------------------- CUSIP No. 584688-10-5 Schedule 13G Page 8 of 8 Pages - ------------------------- --------------------- JOINT FILING AGREEMENT Each of the undersigned hereby agrees and consents that the Schedule 13G filed herewith (the "Schedule 13G") by Quintiles Transnational Corp. ("Quintiles") is filed on behalf of each of them pursuant to the authorization of the undersigned to Quintiles to make such filing and that such Schedule 13G is filed jointly on behalf of each of them, pursuant to Sections 13(d) and 13(g) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, including Rule 13d-1(k)(l). Each of the undersigned hereby agrees that such Schedule 13G is, and any further amendments to the Schedule 13G will be, filed on behalf of each of the undersigned. Each of the persons is not responsible for the completeness or accuracy of the information concerning the other persons making this filing unless such person knows or has reason to believe that such information is inaccurate. This agreement may be signed in counterparts. This agreement is effective as of February 14, 2001. QUINTILES TRANSNATIONAL CORP. By: /s/ James L. Bierman ------------------------------------ Name: James L. Bierman Title: Chief Financial Officer PHARMABIO DEVELOPMENT INC. By: /s/ James L. Bierman ------------------------------------ Name: James L. Bierman Title: Vice President and Treasurer -----END PRIVACY-ENHANCED MESSAGE-----